Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFX-1 in moderate to severe hidradenitis suppurativa
NCT03487276Phase 2Completed
- Sponsor
- InflaRx
- Start
- Feb 2018
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of vilobelimab in hidradenitis suppurativa (HS), sponsored by InflaRx. Started Feb 2018; status: completed.
02
Drugs
vilobelimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03487276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03487276.